Anna Berkenblit
Director/Board Member bij SURROZEN, INC.
Vermogen: 3 M $ op 31-01-2024
Profiel
Anna Berkenblit is currently the Director at Surrozen Operating, Inc. and an Independent Director at Surrozen, Inc. She previously worked as the Chief Medical Officer & Senior Vice President at ImmunoGen, Inc., Vice President at Pfizer Inc., Vice President & Head-Clinical Research at AVEO Pharmaceuticals, Inc., and Senior Vice President-Clinical Development at H3 Biomedicine, Inc. Berkenblit received her graduate degrees from Harvard University and Massachusetts Institute of Technology, her undergraduate degree from Yale University, and her doctorate from Harvard Medical School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
IMMUNOGEN, INC.
0.04% | 29-12-2023 | 101 612 ( 0.04% ) | 3 M $ | 31-01-2024 |
Actieve functies van Anna Berkenblit
| Bedrijven | Functie | Begin |
|---|---|---|
| SURROZEN, INC. | Director/Board Member | 01-08-2018 |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Director/Board Member | 14-03-2019 |
Eerdere bekende functies van Anna Berkenblit
| Bedrijven | Functie | Einde |
|---|---|---|
| IMMUNOGEN, INC. | Chief Tech/Sci/R&D Officer | 31-08-2023 |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | 01-01-2015 |
| AVEO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-01-2013 |
| PFIZER, INC. | Corporate Officer/Principal | 01-09-2011 |
Opleiding van Anna Berkenblit
| Harvard University | Graduate Degree |
| Massachusetts Institute of Technology | Graduate Degree |
| Yale University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| SURROZEN, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
